United States first country to launch Saxenda

1 min read

The FINANCIAL — Novo Nordisk on April 22 announced that Saxenda (liraglutide 3 mg) is now available in the United States (US). Saxenda is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management, approved in the US, EU and Canada.

In the US, it is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI >=30 kg/m2) or who are overweight (BMI >=27 kg/m2) in the presence of at least one weight-related comorbid condition, according to Novo Nordisk.

Saxenda was evaluated in the SCALE(TM) (Satiety and Clinical Adiposity-Liraglutide Evidence in Nondiabetic and Diabetic people) phase 3 clinical trial programme, which involved more than 5,000 study participants who have obesity (BMI >=30 kg/m2) or who are overweight (BMI >=27 kg/m2) with weight-related comorbidities. Trial data showed that Saxenda®, in combination with a reduced-calorie diet and increased physical activity, resulted in greater weight loss than reduced calorie diet and physical activity alone.1

“We are pleased to make this new treatment option available, which we believe has the potential to help people with obesity lose weight and reduce weight-related comorbidities” said Executive Vice President Jakob Riis, Marketing, Medical Affairs & Stakeholder Engagement of Novo Nordisk. “The launch of Saxenda is an important milestone in Novo Nordisk’s long-term commitment to obesity treatment and we look forward to launching Saxenda in other countries later in 2015.”

Recognised as a disease by the American Medical Association and other medical societies,obesity has grown in prevalence in the United States and around the world.2-4 Affecting approximately 35% of the US adult population in 2011-2012, obesity is associated with serious co-morbidities, including type 2 diabetes, heart disease and certain types of cancer.5,6  Novo Nordisk expects to launch Saxenda® in several other markets starting in 2015.


Leave a Reply